What is HC Wainwright’s Forecast for ATRA Q3 Earnings?

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) – Equities researchers at HC Wainwright issued their Q3 2025 EPS estimates for Atara Biotherapeutics in a research note issued to investors on Tuesday, August 19th. HC Wainwright analyst R. Burns forecasts that the biotechnology company will post earnings per share of ($0.83) for the quarter. The consensus estimate for Atara Biotherapeutics’ current full-year earnings is ($10.39) per share. HC Wainwright also issued estimates for Atara Biotherapeutics’ Q4 2025 earnings at ($0.68) EPS, FY2025 earnings at $1.72 EPS and FY2026 earnings at $0.87 EPS.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its earnings results on Monday, August 11th. The biotechnology company reported $0.19 EPS for the quarter, topping the consensus estimate of ($0.32) by $0.51. Atara Biotherapeutics had a net margin of 3.07% and a negative return on equity of 8.34%. The company had revenue of $17.58 million for the quarter, compared to analysts’ expectations of $4.23 million.

Atara Biotherapeutics Trading Down 2.3%

Shares of ATRA opened at $11.49 on Thursday. Atara Biotherapeutics has a 12 month low of $5.01 and a 12 month high of $18.70. The firm’s 50 day moving average is $10.03 and its 200-day moving average is $8.22. The stock has a market capitalization of $80.66 million, a PE ratio of -26.72 and a beta of 0.26.

Insider Activity at Atara Biotherapeutics

In other Atara Biotherapeutics news, major shareholder Innovation Ltd Panacea bought 55,000 shares of the stock in a transaction dated Friday, August 15th. The shares were bought at an average cost of $12.19 per share, with a total value of $670,450.00. Following the completion of the acquisition, the insider owned 1,405,000 shares of the company’s stock, valued at $17,126,950. This trade represents a 4.07% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 4.00% of the company’s stock.

Institutional Trading of Atara Biotherapeutics

Large investors have recently made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Atara Biotherapeutics during the 4th quarter worth approximately $48,000. Raymond James Financial Inc. acquired a new stake in shares of Atara Biotherapeutics during the 2nd quarter worth approximately $31,000. Northern Trust Corp acquired a new stake in shares of Atara Biotherapeutics during the 4th quarter worth approximately $149,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Atara Biotherapeutics during the 4th quarter worth approximately $169,000. Finally, Birchview Capital LP acquired a new stake in shares of Atara Biotherapeutics during the 4th quarter worth approximately $293,000. Institutional investors and hedge funds own 70.90% of the company’s stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.